Benign Prostatic Hyperplasia (BPH) Treatment Devices Market Size, Share Global Analysis Report, 2024 – 2032

Industry Insights

[209+ Pages Report] According to Facts & Factors, the global benign prostatic hyperplasia (BPH) treatment devices market size in terms of revenue was valued at around USD 1520.17 million in 2023 and is expected to reach a value of USD 3240.33 million by 2032, growing at a CAGR of roughly 8.77% from 2024 to 2032. The global benign prostatic hyperplasia (BPH) treatment devices market is projected to grow at a significant growth rate due to several driving factors.

Market Overview

Benign prostatic hyperplasia (BPH) treatment devices are medical devices used to treat the enlargement of the prostate gland in men. The prostate gland is a small, walnut-shaped gland that sits just below the bladder and surrounds the urethra. As men age, the prostate gland can enlarge, which can narrow the urethra and cause urinary problems.

There are a number of different BPH treatment devices available, each with its own advantages and disadvantages. The best device for a particular man will depend on the severity of his symptoms, his overall health, and his preferences.

Key Highlights

• The benign prostatic hyperplasia (BPH) treatment devices market has registered a CAGR of 8.77% during the forecast period.
• In terms of revenue, the global benign prostatic hyperplasia (BPH) treatment devices market was estimated at roughly USD 1520.17 million in 2023 and is predicted to attain a value of USD 3240.33 million by 2032.
• The growth of the benign prostatic hyperplasia (BPH) treatment devices market is being propelled by technological advancements and growing awareness and diagnosis.
• By region, North America currently leading the global market.

Growth Drivers:

• Aging Population: As the global population ages, the incidence of BPH naturally increases, driving demand for treatment options.
• Minimally Invasive Techniques: The rise of minimally invasive procedures like laser and radiofrequency ablation offers faster recovery times and reduced side effects, making them more attractive to patients.
• Emerging Markets: Growing healthcare infrastructure and increasing disposable income in developing countries create new markets for BPH treatment devices.
• Value-Based Healthcare: Shift towards value-based healthcare systems incentivizes treatments that are cost-effective and improve patient outcomes, favoring minimally invasive devices.

Restraints:

• High Cost of Devices: Advanced BPH treatment devices can be expensive, limiting accessibility for some patients and healthcare institutions.
• Reimbursement Challenges: Reimbursement policies by insurance companies may not adequately cover newer BPH treatment devices.
• Lack of Awareness: Limited public awareness about BPH and treatment options can hinder early diagnosis and treatment.

Opportunities:

• Non-surgical and Office-based Procedures: Development of even less invasive and in-office BPH treatment procedures can further increase patient adoption.
• Technological Advancements: Improvements in laser, radiofrequency, and other BPH treatment technologies can enhance effectiveness and reduce side effects.
• Telemedicine and Remote Consultation: Telemedicine consultations hold promise for easier access to BPH diagnosis and potentially remote monitoring of treatment.
• Patient Education and Engagement: Increased patient education initiatives can raise awareness of BPH and treatment options, leading to earlier intervention.

Challenges:

• Clinical Data and Long-term Studies: Newer BPH treatment devices may require more clinical data and long-term studies to establish their safety and long-term efficacy.
• Competition: The BPH treatment device market is competitive, with established players and new entrants vying for market share.
• Regulatory Requirements: Navigating stringent regulatory processes for device approval can delay market entry of innovative BPH treatment devices.

Benign Prostatic Hyperplasia (BPH) Treatment Devices Market: Segmentation Analysis

The global benign prostatic hyperplasia (BPH) treatment devices market is segmented based on product, procedure type, end user, and region.

Segmentation Analysis by Product:

Based on Product, the global benign prostatic hyperplasia (BPH) treatment devices market is bifurcated into resectoscopes, urology lasers, radiofrequency ablation devices, prostatic stents and implants. Resectoscopes are instruments used in Transurethral Resection of the Prostate (TURP), a common surgical procedure for BPH. Urology Lasers segment includes various lasers used for minimally invasive BPH procedures like laser enucleation of the prostate. Radiofrequency Ablation Devices use radiofrequency energy to destroy prostate tissue causing BPH. Prostatic Stents and Implants includes devices like urethral stents to open up the blocked urinary passage and implants to support the prostate.

Segmentation Analysis by Procedure Type:

Based on Procedure Type, the global benign prostatic hyperplasia (BPH) treatment devices market is categorized into transurethral microwave therapy (TUMT), transurethral resection of the prostate (TURP), transurethral needle ablation (TUNA), laser surgery, and urolift surgery. Transurethral Microwave Therapy (TUMT) uses microwave energy to heat and destroy prostate tissue. Transurethral Resection of the Prostate (TURP) is Surgical removal of prostate tissue with a resectoscope. Transurethral Needle Ablation (TUNA) uses radiofrequency needles to ablate prostate tissue. Laser Surgery utilizes lasers for minimally invasive prostate tissue removal. Urolift Surgery Implants tiny devices to hold the prostate in place and open the urethra.

Segmentation Analysis by End User:

Based on End User, the global benign prostatic hyperplasia (BPH) treatment devices market is categorized into hospitals, ambulatory surgical centers (ASCs), and clinics. Hospitals are primary users of BPH treatment devices for surgeries and procedures. Ambulatory Surgical Centers (ASCs) is outpatient clinics equipped for minimally invasive BPH procedures. In Clinics, physician offices may offer some BPH procedures using relevant devices.

Recent Developments

In May 2023, Teleflex Incorporated announced significant research findings regarding the long-term effectiveness of the prostatic urethral lift procedure using the UroLift System. The data revealed that this procedure had fewer complications compared to other traditional minimally invasive procedures for benign prostatic hyperplasia (BPH).

In May 2021, Olympus Corporation announced the acquisition of Medi-Tate, a medical equipment maker.

Report Scope

Benign Prostatic Hyperplasia (BPH) Treatment Devices Market: Regional Analysis

• North America dominates the global market

North America currently holds the dominant position in the BPH treatment devices market due to factors like high disposable income, established healthcare infrastructure, and early adoption of new technologies. The CAGR (Compound Annual Growth Rate) for this region is expected to be steady but slightly lower compared to other regions.

Europe is another major market for BPH treatment devices due to its large aging population and well-developed healthcare systems. The European market is projected to have a healthy CAGR.

Asia Pacific is expected to witness the fastest growth in the BPH treatment devices market due to a rapidly aging population, rising healthcare expenditure, and increasing awareness about BPH. The CAGR for this region is anticipated to be the highest.

Benign Prostatic Hyperplasia (BPH) Treatment Devices Market: Competitive Landscape

Some of the major players in the global benign prostatic hyperplasia (BPH) treatment devices market include:

• Boston Scientific Corporation
• Coloplast Corp
• Cook Medical
• Endo Pharmaceuticals Inc.
• Karl Storz
• Medifocus
• Olympus America
• PROCEPT BioRobotics Corporation
• Richard Wolf GmbH
• Teleflex Incorporated
• Urotronic
• biolitec AG

The global benign prostatic hyperplasia (BPH) treatment devices market is segmented as follows:

Segmentation Analysis By Product:

• Resectoscopes
• Urology Lasers
• Radiofrequency Ablation Devices
• Prostatic Stents and Implants

Segmentation Analysis By Procedure Type:

• Transurethral Microwave Therapy (TUMT)
• Transurethral Resection of The Prostate (TURP)
• Transurethral Needle Ablation (TUNA)
• Laser Surgery
• Urolift Surgery

Segmentation Analysis By End User:

• Hospitals
• Ambulatory Surgical Centers (ASCs)
• Clinics

By Regional Segment Analysis

• North America
  • The U.S.
  • Canada
  • Mexico
• Europe
  • France
  • The UK
  • Spain
  • Germany
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • Southeast Asia
  • Rest of Asia Pacific
• The Middle East & Africa
  • Saudi Arabia
  • UAE
  • Egypt
  • Kuwait
  • South Africa
  • Rest of the Middle East & Africa
• Latin America
  • Brazil
  • Argentina
  • Rest of Latin America